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Background: Alpha-1-microglobulin (A1M), a small lipocalin protein found in plasma and
tissues, has been identified as a heme1 and radical scavenger that may participate in the
mitigation of toxicities caused by degradation of hemoglobin. The objective of this work
was to investigate heme interactions with A1M in vitro using various analytical techniques
and to optimize analytical methodology suitable for rapid evaluation of the ligand binding
properties of recombinant A1M versions.
Methods: To examine heme binding properties of A1M we utilized UV/Vis absorption
spectroscopy, visible circular dichroism (CD), catalase-like activity, migration shift
electrophoresis, and surface plasmon resonance (SPR), which was specifically developed
for the assessment of His-tagged A1M.
Results: The results of this study confirm that A1M is a heme binding protein that can
accommodate heme at more than one binding site and/or in coordination with different
amino acid residues depending upon heme concentration and ligand-to-protein molar ratio.
UV/Vis titration of A1M with heme revealed an unusually large bathochromic shift, up to
38 nm, observed for heme binding to a primary binding site. UV/Vis spectroscopy, visible
CD and catalase-like activity suggested that heme is accommodated inside His-tagged
(tgA1M) and tagless A1M (ntA1M) in a rather similar fashion although the His-tag is very
likely involved into coordination with iron of the heme molecule. SPR data indicated kinetic
rate constants and equilibrium binding constants with KD values in a μM range.
Conclusions: This study provided experimental evidence of the A1M heme binding
properties by aid of different techniques and suggested an analytical methodology for a
rapid evaluation of ligand-binding properties of recombinant A1M versions, also suitable
for other His-tagged proteins.
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INTRODUCTION
Heme (iron-protoporphyrin IX) is a prosthetic group of
hemoglobin (Hb), myoglobin and many other hemoproteins that
perform a wide range of biological functions such as oxygen
delivery, iron storage, electron transfer, and substrate oxidation
(Smith et al., 2010). However, once released from Hb and other
hemoproteins, heme is capable of generating reactive oxygen
species that can oxidatively damage lipids and proteins, lead-
ing to oxidative stress and cell and tissue damage (Jeney et al.,
2002; Buehler et al., 2011). Heme toxicity is seen in several
Abbreviations: A1M, α1-microglobulin; CD, circular dichroism; CE, Cotton
Effect; DMSO, dimethyl sulfoxide; HA, human albumin; His8, histidine octapep-
tide; HPX, hemopexin; L/P, ligand-to-protein (molar) ratio; ntA1M, non-tagged
alpha-1-microglobulin; PBS, phosphate buffer saline; SPR, surface plasmon reso-
nance; tgA1M, His-tagged alpha-1-microglobulin; RU, response units.
pathological conditions including hemolytic disorders such as
malaria, β-thalassemia and sickle-cell disease (Vinchi et al., 2013;
Dutra and Bozza, 2014). Recently, heme was shown to bind
specifically to the Toll-like Receptor (TLR4) leading to endothe-
lial cell activation and vaso-occlusion in murine sickle cell disease
(Belcher et al., 2014).
Hb, the most abundant heme-containing protein in the cir-
culation, is the major source of free heme due to catabolism
of extracellular Hb in hemolytic disorders. Exogenous sources
of free heme include red blood cell (RBC) preparations during
storage (Buehler et al., 2011), heme-based therapeutics (such as
Panhematin, hemin for injection, and heme arginate) that are
1The term “heme” is used in this article to denote both the ferrous and ferric
forms.
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used for the treatment of porphyrias (Tenhunen and Mustajoki,
1998; Siegert and Holt, 2008), and Hb-based blood substitutes
(Alayash, 2014). In the circulation, the free heme redox toxicity is
mitigated by several innate defense mechanisms, including heme
sequestration by plasmatic major heme scavengers hemopexin,
albumin, and some other proteins (Ascenzi et al., 2005; Buehler
et al., 2011). A1M, also known as protein HC, has emerged
among anti-oxidative defense mechanisms as a tissue house-
keeping protein which is capable of capturing heme and free
radicals (Allhorn et al., 2002; Åkerström et al., 2007; Olsson et al.,
2012; Åkerström and Gram, 2014), as well as reducing oxida-
tive lesions (Allhorn et al., 2005; Olsson et al., 2008; Rutardottir
et al., 2013). This small heterogeneously charged glycoprotein
(∼26 kDa) belongs to the lipocalin protein family, a group of
small extracellular proteins that are known for a great diversity
of their primary sequence, but share a well-conserved tertiary
structure (Åkerström et al., 2000; Flower, 2000). The lipocalins
share a common fold, a β-barrel consisting of eight antiparallel
β-strands with a closed bottom, an open end and a hydrophobic
pocket which can carry small lipophilic ligands (Ganfornina et al.,
2006). Whereas precise physiological functions of A1M and many
other lipocalins are not defined yet, these proteins are known for
their ligand-binding properties and thus, seem to play an impor-
tant role in binding, storage and transport of small lipophilic
molecules (Breustedt et al., 2006). A1M was shown to bind heme
in different species (Allhorn et al., 2002; Larsson et al., 2004).
Because of its radical and heme binding properties and antiox-
idant potential, A1M is being considered for several therapeutic
applications (Åkerström and Gram, 2014), and recombinant His-
tagged A1M has been successfully employed for in vivo treatment
of preeclampsia in a sheep model (Wester-Rosenlöf et al., 2014)
and Hb-induced glomerular dysfunction in rats (Sverrisson et al.,
2014).
A previous study suggested that each A1M-molecule binds
two heme-groups (Siebel et al., 2012). The aim of this study was
to characterize the interactions of recombinant A1M with heme
using various analytical techniques. Our analytical methodology
included (a) UV/Vis monitoring of the A1M titration by heme,
(b) evaluation of a possible involvement of the recombinant A1M
His-tag into a coordination with iron of the heme molecule, (c)
visible circular dichroism (CD) to characterize heme/A1M inter-
actions by aid of protein-induced chirality (induced CD), and (d)
development of surface plasmon resonance (SPR) analysis suit-
able for the immobilization of recombinant A1M by the His-tag
per se to study the interactions with heme and/or other ligands
without removal of the tag.
MATERIALS AND METHODS
MATERIALS
Hemin, dimethyl sulfoxide (DMSO), L-His, imidazole, and essen-
tially fatty acid free human serum albumin (HA) were pur-
chased from Sigma Chemical Co. (St. Louis, MO). Recombinant
human A1Mwith an N-terminal His8-tag (tgA1M) was expressed
and purified in E.coli as described (Kwasek et al., 2007), with
the addition of ion-exchange chromatography and size exclu-
sion purification steps performed as follows. The protein solu-
tion was applied to a column of DEAE-Sephadex A-50 (GE
Healthcare, Uppsala, Sweden) equilibrated with the starting
buffer (20mM Tris-HCl, pH 8.0). A1M was eluted at a flow
rate of 1ml/min using a linear pH gradient consisting of 250ml
starting buffer and 250ml elution buffer (20mM Tris-HCl,
0.15M NaCl, pH 8.0). Size-exclusion chromatography was run
on a Superose 12 column obtained from GE Healthcare using
Äkta purifier 10 system (GE Healtcare) run at a flow-rate of
1ml/min. Notag A1M (ntA1M) was a obtained from A1M
Pharma (Lund, Sweden). Research grade CM5 sensor chips, NTA
sensor chip, 1-ethyl-3-(3-dimethyl-aminopropyl)-carbodiimide
hydrochloride (EDC), N-hydroxysuccinimide, ethanolamine–
HCl, HBS–P buffer (0.01M HEPES, pH 7.4, 0.15M NaCl,
0.005% surfactant P20), Phosphate buffer saline, 10X (PBS)
(0.1M phosphate buffer with 27mM KCl and 1.37M NaCl,
pH 7.4), acetate buffer (pH 5.0), NaOH (50mM), and deion-
ized water were from GE Healthcare (Piscataway, NJ). Anti-His
mouse IgG1 monoclonal antibodies were purchased from R&D
Systems (Minneapolis, MN). Hemopexin (HPX) was fromAthens
Research Technologies (Athens, GA). Other chemicals were ana-
lytical grade from Fisher Scientific (Fair Lawn, NJ).
PREPARATION OF PROTEIN SOLUTIONS
Protein stock solutions (22 and 45μM) of A1M, HA, HPX were
prepared in 20mM Tris-HCl, 0.15M NaCl, pH 8.0 (Tris buffer),
aliquoted and stored frozen at −70◦C until use. A1M samples in
PBS or Tris buffer were prepared by dilution of the concentrated
stock solutions prior to use. Concentrations of the reference
proteins HA and HPX were determined spectrophotometrically
using a molar extinction coefficient of 5.5 × 104 M−1cm−1 for
HA (Gill and von Hippel, 1989) and 1.1 × 105 M−1cm−1 for
apo-HPX (Eskew et al., 1999).
PREPARATION OF IMIDAZOLE, L-HIS AND HIS8 SOLUTIONS
Imidazole and L-His solutions were prepared in Tris buffer at con-
centrations 100mM and 50mM, respectively, to provide a large
excess over the heme to be added. A His-octapeptide was synthe-
sized at CBER Core facility (Silver Spring, MD) and dissolved to
100mM in Tris buffer prior to adding of heme aliquots followed
by UV/Vis spectral measurements.
PREPARATION OF HEME SOLUTION
Heme stock solutions (2.4 and 1.2mM) were freshly prepared in
DMSO for each experiment, purged with argon and stored (pro-
tected from light) at 4◦C during use. The heme concentrations
in the stock solutions were determined spectrophotometrically
using heme molar extinction coefficient of 170,000M−1 cm−1
at λmax 404 nm (Collier et al., 1979).
UV/VIS MEASUREMENTS
UV/Vis electronic absorption spectra were measured on Agilent
HP8453 UV-visible spectrophotometer (Agilent Technologies
Deutschland GmbH, Germany) at 25 ± 0.2◦C in a quartz cuvette
of 1 cm pathlength. The measurements were performed in the
range of 250–700 nm for A1M interactions with heme. UV/Vis
differential spectra of the heme/A1M samples were measured
using A1M as a blank.
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A1M TITRATION WITH HEME
Titration of A1M samples with heme was performed using
45μM A1M preparations in Tris buffer. Heme concentration
was increased stepwise by addition of 2μL aliquots of 2.1mM
heme stock solution in DMSO to a 1mL of 45μM protein
solution. UV/Vis and CD recordings were repeated until no sig-
nificant alterations were observed, before the next heme aliquot
was added. During titration the samples were maintained at
room temperature, protected from light and periodically flashed
by argon. Initial 45μM A1M solutions served as a blank. The
total amount of DMSO in the titration samples did not exceed
2% v/v. Titration of A1M with heme was carried out until
the ligand-to-protein molar ratio (L/P) was 1.4. Since signs of
turbidity and slight precipitation were observed for the sam-
ples with high heme content, only the data up to L/P 1.0
were included.
MIGRATION SHIFT ELECTROPHORESIS
Tris buffer with 5μM tgA1M or ntA1M was incubated for 15min
at room temperature with 50, 5, 0.5, and 0μM heme. Samples
were mixed with equal amounts of sample buffer for native PAGE,
pH 6.8, and subjected to electrophoresis on 12% Criterion™
TGX™ Precast stainfree gels (Bio-Rad) under non-denaturing
and non-reducing conditions. The gel was first imaged by tryp-
tophan fluorescence with a BioRad GelDoc MP Imaging system
and then stained with Coomassie Brilliant Blue R-250 (BDH
Chemicals, Ltd. Poole, UK).
CD MEASUREMENTS
CD measurements were performed using a Jasco J-815
Spectropolarimeter (JASCO Co., Japan) with the tempera-
ture maintained at 25 ± 0.2◦C by a Peltier thermostat. The
spectra were measured at a scan speed of 100 nm/min, bandwidth
of 1.0 nm, and resolution of 0.2 nm and accumulated in triplicate.
All samples containing heme were measured for protein-induced
CD in the near-UV—visible range from 700 to 300 nm (referred
to as visible CD). To accumulate the induced CD, A1M prepara-
tions were used at a concentration ∼45μM in Tris buffer, and
the measurements of heme/A1M samples were performed in a
quartz cuvette with 1 cm pathlength. Protein alone was used as a
blank. Heme/HPX and heme/HA samples were recorded at the
same concentration, but in a cuvette with a shorter pathlength
(5mm) because of the strong induced CD, and then the spectra
were normalized. An ellipticity of CD spectra was expressed in
millidegrees (mdeg).
SURFACE PLASMON RESONANCE
SPR experiments were performed using Biacore T200 (GE
Healthcare, Piscataway, NJ). About 18,000 response units (RU)
anti-His mouse IgG1 monoclonal antibody (R&D Systems,
Minneapolis, MN) were immobilized on CM5 sensors using the
amine coupling kit. The tagged protein was captured by inject-
ing tgA1M (10μL/min) for 360 s. Heme samples were prepared
prior to injection by serial double dilutions of the initial 100μM
heme solution in PBS-P/5% DMSO to create a range over eight
concentrations (from 100 to 0.625μM). Heme samples prepared
at pH 7.2 and pH 8 were injected over captured A1M for 2min
with a flow 30μL/min at 25◦C. The dissociation was monitored
for 10min. Data were analyzed using the Biacore T200 evalua-
tion software (GE Healthcare), subtracting the reference surface
(immobilized anti-His mouse IgG1 antibody from the captured
A1M surface) and buffer control signals from each curve. Data
were globally fitted by simultaneous numerical integration to
the association and dissociation parts of the interaction, using
the heterogeneous ligand kinetic analysis models. Steady-state
equilibrium was reached during the association phase, global
fitting produced reproducible kinetic parameters. Experimental
Rmaximum response (Rmax) values obtained by global fitting were
comparable to theoretical Rmax values calculated from the molec-
ular masses of the interacting proteins and the immobilization
level. For the interactions with an equilibrium achieved, KD was
also calculated by an equilibrium analysis.
The T200 BIAevaluation software (version 1.0; Biacore AB,
Uppsala, Sweden) offers various reaction models to perform
complete kinetic analyses of the sensorgrams, from which the
heterogeneous ligand binding model were applied. This model
describes an interaction between one analyte and two indepen-
dent ligands or two binding sites of one ligand. The binding curve
obtained is simply the sum of the two independent reactions.
CATALASE-LIKE ACTIVITY ASSAY
Stability of the Soret band intensity and heme accessibility to
hydrogen peroxide in heme/tgA1M and heme/ntA1M samples
in comparison with heme alone in Tris buffer were evalu-
ated using the catalase-like activity assay, as described earlier
(Karnaukhova et al., 2012) with minor modifications. Briefly,
heme/A1M equimolar (L/P 1.0) samples were prepared by adding
21μL of 2.1mM heme stock solution in DMSO to 1mL of 45μM
solutions of tgA1M and ntA1M in Tris buffer. The samples were
incubated at room temperature for 20 h, protected from light.
The complex formation was confirmed by a stable Soret band in
the UV/Vis spectra, i.e., λmax at 411 nm typical for heme/tgA1M
(L/P 1.0) and λmax at 389 nm typical for heme/ntA1M (L/P 1.0),
respectively. As a reference, a heme sample in Tris buffer was
freshly prepared the same way and used immediately in view of
its limited stability in aqueous solutions. The samples were nor-
malized to adjust their Soret bands to approximately the same
intensity (∼0.56 AU) by dilution with Tris buffer. After addition
of a 7μL aliquot of 50mM H2O2 solution to 1mL of the sample
(∼8-fold excess over the heme complex content), the absorption
spectra were taken at the following time points: 30 s, 1, 2, 4, 6, 8,
and 10min.
RESULTS AND DISCUSSION
UV/VIS ASSESSMENT
Due to its hydrophobic nature, free heme possesses a low sol-
ubility in aqueous media and has a tendency to aggregate. In
organic solvents, such as ethanol or DMSO, heme hasmuch better
solubility and exhibits a strong Soret band at 404–405 nm, sta-
ble for few days. When an aliquot of a heme stock solution in
DMSOwas added to a buffer solution, a broad Soret band around
380 nm with a relatively low intensity was observed which further
decreased with time (Figure 1A). However, when a heme aliquot
was added to the same buffer (Tris, pH 8), containing A1M, the
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FIGURE 1 | UV/Vis electronic absorbance data. (A) UV/Vis spectra of
heme in Tris buffer and DMSO; the same aliquot of 1.28mM heme stock
solution was added to 1mL of buffer or DMSO, respectively; inset shows
heme structure; (B) time-course absorbance spectra of 45μM A1M
sample containing 0.1 molar equivalent of heme (L/P 0.1); (C) differential
UV/Vis spectra of the A1M titration by heme (the initial spectrum of 45μM
A1M, shown by thin dotted trace, has been subtracted by running the
A1M sample as a blank prior to adding heme); the spectra are shown for
the time point 40min; all titration samples were measured in 10mm
pathlength cuvette, except the last one (L/P 1.0) which spectrum has been
recorded in 5mm pathlength cuvette and then normalized to 10mm path;
(D) the absorbance intensities of the Soret band of heme complexes with
A1M as plotted at the wavelengths 422 nm (λmax at low L/P) and 411 nm
(λmax at higher L/P).
observed spectral alterations included (a) a drastically red-shifted
Soret band (∼38 nm shifted in comparison with the spectrum
of heme alone), (b) increasing intensity of this band, which
remained stable when reaches maximum, and (c) characteris-
tic isosbestic point for the spectra taken at different time-points
(Figure 1B). These features are indicative of a complex formation
between heme and A1M. Figure 1C shows UV/Vis absorption
spectra of the A1M titration with heme which was performed
by adding of small calculated aliquots of heme stock solution in
DMSO to 45μM A1M in Tris buffer to increase the heme con-
tent in the heme/A1M mixture by 0.1 molar equivalent steps. As
heme accomodation in A1M takes time (Figure 1B), each spec-
trum shown in Figure 1C was taken at a time point not less than
40min after adding next heme aliquot to allow the reaction mix-
ture to reach its equilibrium state, when no further significant
alterations in the intensity or position of the Soret band were
observed. Further titration resulted in a gradual increase of the
Soret band intensity that was almost linearly proportional to the
heme content in the sample (Figures 1C,D), and in the character-
istic alteration of the Soret band λmax from 422 nm (at low L/P of
0.1 and 0.2) to λmax at 411–412 nm observed for higher L/P.
As evident from the spectra obtained for the samples with
heme content corresponding to low ligand-to-protein molar
ratios (L/P) such as 0.1 and 0.2, heme in A1M solution exhibited
a Soret band at 422 nm that is strongly red-shifted in comparison
with heme in buffer alone (384 nm, Figure 1A). A bathochromic
shift in UV/Vis absorption spectra provides evidence of a ligand
complex formation with the host protein (Zsila et al., 2003, 2005;
Neya et al., 2010). A large excess of the protein over heme pro-
motes binding of heme primarily to the protein site(s) of high
affinity, and a heme co-ordination by amino acid residues inside
the primary binding site(s) may result in a higher energy level and
thus, a red-shifted Soret band. Interestingly, the bathochromic
shift observed for heme/A1M (∼38 nm) is much larger than those
of plasma major heme scavengers hemopexin and human albu-
min which possess high affinities for heme and well-fit heme
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primary binding sites, and are characterized by Soret bands at 413
and 405 nm, respectively.
A recent report (Siebel et al., 2012) suggested binding of two
molecules of heme to each A1M molecule. This is supported
by the results shown in Figure 1. Titration of A1M with heme
(Figures 1C,D) suggested heme binding to a primary binding site
of high affinity at low L/P and also to a hypothetical secondary
site of lower affinity at higher L/P. With increasing heme content,
heme continued to fill both binding sites, and at higher L/P val-
ues (starting L/P 0.6) the intensity of the Soret band at 411 nm
prevailed over that at 422 nm (Figure 1D). At a heme-to-protein
ratio higher than 1.2 (i.e., heme concentrations beyond 50μM),
some turbidity and slight precipitation could be observed. UV/Vis
spectra of the supernatant showed a broad band around 405 nm
with a shoulder at 355 nm, very likely due to an overlapping of
the Soret bands corresponding to aforementioned sites, free and
aggregated heme in the solution, and non-specific heme binding
at the protein surface, which, however, were beyond the scope of
this study.
Thus, UV/Vis titration provided strong experimental evidence
of the heme binding to A1M. The results were compatible with
two heme binding sites as suggested previously (Siebel et al., 2012)
and also raised the question of the nature of this extremely red-
shifted Soret band.
It is well known that heme can interact with His-tags (Asher
and Bren, 2010) and can be involved in bis-His (hexa-) coordina-
tion (Owens et al., 2013). Therefore, the large bathochromic shift
observed for heme/A1M samples (Figure 1) posed the question
whether the His-tag may have an impact on the heme-binding.
First, a native PAGE was run demonstrating that both His-
tagged A1M (tgA1M) and tagless A1M (ntA1M) indeed bind
the heme molecule (Figure 2). Thus, the migration of both tg-
and nt-A1M was slowed by the heme bound (panel A), and the
tryptophan-fluorescence completely quenched (panel B). A sim-
ilar dose-response of migration shift and fluorescence quenching
was noted for the two forms, suggesting similar affinities and
coordination for tg- and nt-A1M. No effect on migration or flu-
orescence could be seen on the negative control ovalbumin by
addition of heme.
To evaluate a possible involvement of the 8-mer His-tag in the
hexa-coordination of heme iron, we first studied heme behavior
in the mixtures with imidazole and L-His in comparison with
heme in buffer alone (Figure 3A). In the L-His solutions in Tris
buffer, heme exhibits a strong broad Soret band around 400 nm
(Figure 3A) which is ∼16 nm red-shifted in comparison with
heme in buffer alone. Even more remarkable, added to the imi-
dazole solution in buffer, heme exhibits a strong Soret band at
436 nm with a shoulder at around 400 nm and two well-defined
bands in the visible range, at 541 and 567 nm (Figure 3A). Both
experiments suggest that imidazole side chains of the His-tagged
protein may participate in the heme iron hexa-coordination by
a sandwich structure when heme content is low in compari-
son with the protein (such as L/P 0.1 and 0.2 discussed above).
However, when we examine His-octapeptide which was specif-
ically synthesized to verify whether His-tag alone may provide
heme hexa-coordination to cause a large bathochromic shift, such
as ∼38 nm, no significant difference was observed between the
FIGURE 2 | Native gel data for heme/A1M samples. tgA1M and ntA1M
(5μM) were incubated with 50, 5, and 0.5 and 0μM heme for 15min at
room temperature, and separated by electrophoresis in a 12% Criterion™
TGX™ Precast stainfree Gels under non-denaturing and non-reducing
conditions. The gels were either stained with Coommassie Brilliant Blue
(A) or imaged by tryptophan fluorescence with a digital BioRad imager (B).
spectra of heme in His8-peptide solution and heme in buffer
solution alone (Figure 3B). The λmax (384 nm) of the absorption
band of heme/His8 sample (Figure 3B) was very much simi-
lar to that of heme in buffer alone (Figure 3A) as well as the
decrease of its intensity in time (broken trace corresponding
to 20 h in Figure 3B). Thus, contrary to imidazole and histi-
dine, no sign of a complex formation with heme was observed
for synthetic His-octapeptide under experimental conditions
used.
This subject was further investigated with tagless A1M.
Figure 4A shows differential UV/Vis titration spectra of ntA1M
conducted the sameway as that shown in Figure 1C. UV/Vis spec-
trum of the heme/ntA1M mixture of L/P 0.1 was characterized
by a broad Soret band around 392 nm, which is only 8 nm red-
shifted in comparison with that of heme in buffer alone (384 nm).
UV/Vis spectra corresponding to further titration of ntA1M with
heme demonstrated similar trends to the Soret band blue shifting,
however from 392 to 388 nm (Figures 4A,D), and an almost lin-
ear dependence between the intensity of the Soret band and heme
content in the sample (not shown) as those observed for tgA1M.
Comparison of the two titration sets demonstrates a difference
between each pair of the tgA1M and ntA1M samples of the same
L/P at every step of the titration in terms of Soret band λmax and
shape of the spectra. As evident from the spectra overlays exem-
plified in Figure 4 for L/P 0.1 (panel B) and L/P 0.6 (panel C),
UV/Vis spectra of heme/tgA1M samples are significantly more
narrow than those of heme/ntA1M, and the λmax values of the
corresponding Soret bands differ by 30 nm and 28 nm, respec-
tively. Figure 4D provides a summary of the λmax values for the
titration of tagged and tagless A1M variants over the entire heme
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FIGURE 3 | UV/Vis spectral evaluation of possible bathochromic shift
due to imidazole-containing compounds. (A) Absorbance spectra of
heme in Tris buffer alone, in 0.1M L-His, and in 0.1M imidazole
solutions, as labeled; (B) heme in 50mM solution of His8-peptide in Tris
buffer: 30 s after adding heme aliquot and 20 h later, as marked; for
details see Materials and Methods.
FIGURE 4 | UV/Vis absorbance data for ntA1M and comparison with
tgA1M. (A) UV/Vis titration of ntA1M by heme (under conditions used for
tgA1M, Figure 1C); (B,C) UV/Vis spectra of heme complexes with tg- and
nt-A1M samples at low (L/P 0.1) and higher (L/P 0.6) heme-to-A1M molar
ratio; (D) alterations of the Soret band λmax of heme/tgA1M and heme
/ntA1M samples of the titration sets shown in Figures 1C, 3A.
concentrations range used in this study. This plot implicates a
His-tag involvement in the heme interactions with A1M, but also
demonstrates a characteristic two-phase titration profile suggest-
ing that heme binding to both tgA1M and ntA1M proceeds at two
(primary and secondary) binding sites.
INDUCED CIRCULAR DICHROISM
To provide more insight into the nature of the heme binding
to A1M, we carried out a CD study in the visible range which
may reflect heme induced optical activity due to its interaction
with A1M, because otherwise heme per se is an optically inactive
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molecule. As demonstrated in Figure 5, neither heme nor A1M
exhibited any CD in the visible range (dotted red and gray traces
at zero-line, respectively). However, when the same amount of
heme was added to the buffer solution containing A1M, a rapidly
arising Cotton Effect (CE) was observed, a phenomenon known
as protein-induced chirality (Zsila et al., 2004; Karnaukhova,
2007; Nagai et al., 2014). Further conformational changes (1 and
20 h traces are shown) were seen over time, with a slowly rising
Soret CD band at 403 nm as the most prominent feature.
FIGURE 5 | CD dynamics of heme binding to tgA1M. The spectra
correspond to 40 μM heme in Tris buffer alone (red dotted trace at the
baseline), and in 45 μM A1M solution at the time points 10min, 1 h, and
20 h, respectively (black traces). Gray spectrum corresponds to 45μM A1M
in Tris buffer alone.
The induced CD spectra shown in Figure 5 for an equimolar
mixture of heme and tgA1M, illustrate the dynamics of the com-
plex formation. Contrary to UV/Vis absorption spectra, which
reflect spectral properties of all heme species in the sample (free,
bound to the protein internal binding site, or associated with pro-
tein at the surface), protein induced CD spectra, by definition,
relate only to that part of heme which exhibits optical activity
due to chiral perturbation to its structure per accomodation in
the protein binding site. The CD spectra shown in Figure 5, in
their original unsmoothed form, reflect ongoing conformational
changes of the heme molecule. While at low heme content the
binding to the A1M primary binding site proceeds relatively fast
(with no further significant changes after ∼40min, not shown),
heme binding to the secondary binding site proceeds slowly at
higher heme-to-A1M ratio (Figure 5). It takes almost 20 h to
achieve an equilibrium state with a well-defined positive CE at
403 nm and no further changes. The induced CE is in a good
agreement with the λmax of the Soret band in the complementary
UV/Vis spectrum (which is ∼411 nm for L/P 1.0).
Figure 6 shows induced CD spectra of the heme complexes
with tgA1M (panel A) and ntA1M (B) at L/P 0.1 and 1.0, after
an equilibrium was achieved by each mixture (the spectra were
measured at 20 h after adding heme). According to Figure 5A,
the induced CD of the heme/tgA1M sample with L/P 0.1 demon-
strates a small positive CE at 421 nm, thus reflecting the heme
environment at the primary binding site. The CD spectrum cor-
responding to L/P 1.0 shows significantly different CE at 403 nm,
very likely due to binding of the heme molecule at the secondary
binding site, whereas a shoulder around 420 nm still suggest an
overlap of the induced CD spectra from both binding sites. The
FIGURE 6 | Induced CD data. Selected visible CD spectra of heme complexes with (A) tgA1M and (B) ntA1M, shown for L/P 0.1 (broken trace) and L/P 1.0
(solid trace), and (C) reference proteins HA and HPX. All samples were of approximately the same initial protein concentration, ∼45μM.
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induced CD spectra of heme/ntA1M samples (Figure 6B) are
broader and of lower intensity of the induced CE. While CD
spectrum corresponding to the sample with L/P 0.1 is weak, the
induced CD spectrum of heme/ntA1M of L/P 1.0 shows CE at
the same 403 nm as that observed for heme/tgA1M (panel A),
although of lower intensity. Comparison of the induced CD data
visualizes the impact of His-tag, but also indicates that ntA1M
binds at least one of the heme-groups at the same binding site as
the tagged A1M does, as evident from their CE at 403 nm.
The induced CE observed for heme/A1M samples were com-
pared with those measured for heme/HPX and heme/HA samples
of the same heme-to-protein molar ratio (Figure 6C). Although
the three proteins are quite different, the intensity of the induced
CD is generally determined by the strength of heme interactions
with each protein and geometry of the binding site (Daviter et al.,
2013). Therefore, higher intensities of the induced CD spectra
in case of heme/HPX and heme/HA, in comparison with that of
heme/A1M, suggest that heme binding sites in hemopexin and
albumin are tighter and of higher affinity than those of A1M.
Furthermore, while the CD titration spectra of heme/HPX and
heme/HA at L/P 0.1 and up to 1.0 are indicative of one main
heme binding site, the differences between heme/A1MCD spectra
at low L/P and higher L/P support heme binding at two binding
sites.
SPR KINETICS OF HEME BINDING TO A1M
SPR (Biacore) was used to study the real-time kinetics of the
heme interactions with A1M using different approaches. Our
attempts to immobilize A1M directly on the CM5 surface were
unsuccessful. Instead, we immobilized A1M by using the His-
tag of the recombinant protein as an anchor for immobilization
(Kimple et al., 2010). This approach also has the advantages
of reducing the possible impact of the His-tag on coordination
with heme, and allowing studies of other possible ligands besides
heme. Therefore, we first explored immobilization of tgA1M by
the His-tag using NTA chip as described elsewhere (Khan et al.,
2006; Fischer et al., 2011). However, although tgA1M was suc-
cessfully immobilized on the NTA sensor chip, we experienced
continuous dissociation of the immobilized A1M from the sur-
face, which was also reported for some other proteins (Willard
and Siderovski, 2006; Clow et al., 2008). Instead, we used primary
immobilization of anti-His mouse IgG1 monoclonal antibody
(Franco et al., 2013). With this approach we were able to success-
fully capture the tgA1M to a highly pure homogeneous surface
used for heme binding kinetics over a wide range of heme con-
centrations from 500μMdown to 0.625μM. Interestingly, with a
heme concentration range of 0.625–100μM (Figure 7), the SPR
data were a perfect fit to 1:1 Langmuir binding model, yield-
ing kinetic rate constants ka and kd of 561.1M−1s−1 and 7.75 ×
10−3 s−1, respectively, and resulting in an equilibrium binding
constant KD of 13.82μM. When the heme concentration range
was extended to higher concentrations (up to 500μM), the exper-
imental data fitted better to a 1:2 binding model, thus supporting
two binding site model suggested by Siebel and co-workers (Siebel
et al., 2012). Using this model, the stronger affinity binding site
was characterized by the association (ka) and dissociation (kd)
rates 405.4M−1s−1 and 2.85 × 10−3 s−1, respectively, thus result-
ing in a calculated KD value of 7.02μM. The binding site of
lower affinity was characterized by ka of 110.8M−1s−1 and kd of
0.02106 s−1, yielding a calculated KD value of 190μM. However,
the accuracy of the KD evaluation for the low affinity binding site
can very likely be impacted by a heme tendency to aggregate at
higher concentrations.
For the primary binding site, the SPR results reproducibly
showed KD values in the low micromolar range (as shown above,
13.82 and 7.02μM) which is consistent with that determined ear-
lier by a different technique (Larsson et al., 2004). It is noteworthy
that at neutral buffer, such as pH 7.2 (data not shown) heme affin-
ity to A1M was ∼10-fold weaker than at pH 8, very likely due to a
better heme solubility at more basic conditions. This observation
seems to be in agreement with our CD data as a stronger intensity
of the induced CD was observed for heme/A1M samples at pH 8
than at pH 7.2–7.4 (not shown).
CATALASE-LIKE ACTIVITY ASSESSMENT
The heme/tgA1M and heme/ntA1M samples were assessed for
catalase-like activity in order to evaluate the accessibility of heme
in these complexes to hydrogen peroxide in comparison to that
of free heme in buffer. As shown in Figure 8A, when an aliquot of
hydrogen peroxide is added to a freshly prepared heme solution in
FIGURE 7 | SPR assessment. (A) Sensorgrams of the heme binding to A1M captured by the anti-His mouse IgG1 monoclonal antibody immobilized on CM5
sensor chip; and (B) Steady-state equilibrium analysis and fitting; see details in Materials and Methods.
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FIGURE 8 | Heme catalase-like activity. (A–C) UV/Vis monitoring of the
Soret band intensity of heme samples in Tris buffer alone (A), and in
complexes with tgA1M (B) and ntA1M (C); (D) alterations of the Soret
band initial intensity (%) measured over 10min after addition of hydrogen
peroxide. Heme complexes with tgA1M and ntA1M were prepared 20 h
prior to these measurements, whereas heme/buffer sample of the same
absorbance intensity was freshly prepared; for more details see Materials
and Methods.
Tris buffer, the intensity of its Soret band drastically drops within
first 30 s, and 2min later more than 42% of the initial intensity
is lost. However, when the same amount of hydrogen peroxide is
added to heme/tgA1M and heme/ntA1M solutions in Tris buffer,
a very limited decrease of the Soret band intensity is observed for
both samples (Figures 8B,C). Figure 8D provides a comparative
summary for this functional assessment, suggesting that heme
accessibility in the complexes with tgA1M and ntA1M is almost
the same, and both A1M variants shield ferriheme from oxidation
and partial decomposition by peroxide in a comparable fashion.
BIOLOGICAL IMPLICATIONS
Free heme exerts toxic effects in biological tissues mainly through
oxidative reactions of the iron (Kumar and Bandyopadhyay,
2005). Heme causes tissue injury by catalyzing oxidation of pro-
teins, lipids and DNA. Since the heme group is a lipophilic
molecule it intercalates lipid bilayer membranes and destabi-
lizes plasmamembranes, mitochondria and nucleus. The primary
targets of free heme in blood are the endothelial cells and kid-
neys. Thus, in vivo pro-inflammatory effects and renal toxicity
have been reported in animals (Wagener et al., 2001; Rodriguez
et al., 2003). The free heme toxicity in blood is probably mit-
igated to a large part by albumin and hemopexin, but A1M
has recently been suggested among the innate defense molecules
as having a role primarily in the extravascular compartments
(Åkerström and Gram, 2014). Besides the heme-binding, A1M
also yields antioxidative protection by radical-scavenging and
reductase activity. Together, these three mechanisms gives the
protein a powerful therapeutic potential and it was indeed shown
that recombinant His-tagged A1M could be employed for in vivo
treatment of the pregnancy disease preeclampsia, characterized by
hypertension and kidney dysfunction, in a sheep model (Wester-
Rosenlöf et al., 2014) and Hb-induced glomerular dysfunction in
rats (Sverrisson et al., 2014).
CONCLUSIONS
We have investigated heme interactions with recombinant
A1M using UV/Vis absorption spectrometry, visible CD, SPR,
migration-shift PAGE, and catalase-like activity assay. The latter
four methods have not previously been applied for this purpose
and provide a deeper insight into the dynamics and character
of heme interactions with A1M. The results support the previ-
ously suggested two binding site model with binding affinities
in the micromolar range. For the first time, induced visible CD
visualizes the differences in the heme microenvironment at the
A1M high and low affinity binding sites. The results also show
that His-tagged and tagless A1M bind heme in a similar fashion,
although the His-tag seems to be involved in the coordination
with heme iron. This study thus provides an analytical plat-
form for rapid evaluation of the ligand-binding properties of
recombinant A1M versions including induced visible CD and an
efficient SPR approach based on the capturing of tagged A1M by
using anti-His-tag antibody, which also may be suitable for other
recombinant proteins.
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